VYNE Therapeutics (VYNE) M&A Announcement summary

Merger overview and strategic rationale

• VYNE and Yarrow Bioscience will merge in an all-stock transaction, with Yarrow's CEO Rebecca Frey, Pharm.D., leading the combined company as CEO and Lori Payton, Ph.D., as Chief Development Officer.

• The merger follows a comprehensive strategic review aimed at maximizing stockholder value, including a cash dividend for VYNE stockholders and continued ownership in the new entity.

• Pre-merger VYNE stockholders will receive a cash dividend of $14.5–$16.5 million and own about 3% of the combined company; Yarrow stockholders will own about 97%.

• The combined company will be named Yarrow Bioscience Incorporated and trade on Nasdaq under the ticker YARW, with the merger expected to close in Q2 next year, pending shareholder and regulatory approvals.

• The board of both companies unanimously approved the transaction, subject to customary closing conditions including SEC registration and shareholder approval.

Financial position and investor support

• The combined company is expected to have a cash runway into 2028, supported by $200 million in pre-closing private placements.

• Leading healthcare investors, including RTW Investments, OrbiMed Advisors, Janus Henderson Investors, and others, participated in the financing.

• Gibson, Dunn & Crutcher LLP and Cooley LLP are providing legal counsel, with Wedbush Securities and LifeSci Capital as financial advisors.

Yarrow's pipeline and clinical strategy

• Yarrow focuses on developing YB-101, a first-in-class humanized monoclonal TSHR antibody for Graves' disease and Thyroid Eye Disease (TED).

• YB-101 was in-licensed from GenSci, with Yarrow holding global ex-China rights; GenSci is running a phase I trial in China, with Phase 1 data in TED expected from China.

• Yarrow plans to start a phase 1b/2b trial for Graves' disease in the US and other territories in the first half of 2026.